VerastemVSTM
Market Cap: $114M
About: Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Employees: 73
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
141% more call options, than puts
Call options by funds: $181K | Put options by funds: $75K
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
4% less funds holding
Funds holding: 70 [Q1] → 67 (-3) [Q2]
7.77% less ownership
Funds ownership: 66.89% [Q1] → 59.12% (-7.77%) [Q2]
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
78% less capital invested
Capital invested by funds: $200M [Q1] → $44.7M (-$155M) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Truist Securities Srikripa Devarakonda 65% 1-year accuracy 15 / 23 met price target | 430%upside $15 | Buy Maintained | 13 Aug 2024 |
HC Wainwright & Co. Sean Lee 53% 1-year accuracy 10 / 19 met price target | 147%upside $7 | Buy Maintained | 12 Aug 2024 |
RBC Capital Gregory Renza 56% 1-year accuracy 41 / 73 met price target | 359%upside $13 | Outperform Maintained | 9 Aug 2024 |
B. Riley Securities Kalpit Patel 44% 1-year accuracy 4 / 9 met price target | 147%upside $7 | Buy Maintained | 24 Jul 2024 |
Truist Securities Srikripa Devarakonda 65% 1-year accuracy 15 / 23 met price target | 536%upside $18 | Buy Maintained | 8 Jul 2024 |
Financial journalist opinion
Based on 3 articles about VSTM published over the past 30 days